Table 2.

Comparison of the efficacy and safety of treatment in the three groups

Variable	A group (n = 73)	B group (n = 71)	C group (n = 72)	X2	P
Therapeutic efficacy n (%) abc
Complete normalization individual quantity	61(83.6%)	47(66.2%)	44(61.1%)
Partial improvement individual quantity	4(5.5%)	7(9.9%)	8(11.1%)	9.612	0.008
No improvement individual quantity	8(10.9%)	17(23.9%)	20(27.8%)
Safety n (%) with adverse reactions
Mild	5(6.85%)	6(8.45%)	5(6.94%)	0.168	0.919
Moderate	1(1.4%)	1(1.4%)	1(1.4%)	0.000	1.000
Severe	0(0%)	0(0%)	0(0%)

A group received bicyclol tablets, B group received diammonium glycyrrhizinate enteric–coated capsules, and C group received silibinin capsules.

Statistical significance of differences between groups in therapeutic efficacy:

a : A vs B, significant (P = 0.016).

b: A vs C, very significant (P = 0.003).

c: B vs C, not statistically significant (P = 0.531).